|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,148.00 JPY | +0.28% |
|
+0.07% | +2.63% |
| 07-13 | Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug | MT |
| 07-10 | Health Care Down on Rotation Back to Tech - Health Care Roundup | DJ |
| Market Cap | 3,848B 23.69B 20.71B 19.15B 17.59B 33.26B 2,282B 33.88B 227B 89.43B 1,116B 88.96B 87.03B | P/E 2027 * |
11.2x | P/E 2028 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 3,704B 22.8B 19.93B 18.43B 16.94B 32.01B 2,197B 32.61B 218B 86.09B 1,075B 85.64B 83.78B | EV / Sales 2027 * |
1.64x | EV / Sales 2028 * | 1.62x |
| Free-Float |
97.66% | Yield 2027 * |
3.75% | Yield 2028 * | 3.86% |
Last Transcript: Astellas Pharma Inc.
| 1 day | +0.28% | ||
| 1 week | +0.07% | ||
| Current month | -1.24% | ||
| 1 month | -0.21% | ||
| 3 months | -17.56% | ||
| 6 months | -6.69% | ||
| Current year | +2.63% |
| 1 week | 2,109 |  | 2,176 |
| 1 month | 2,105 | | 2,216.5 |
| Current year | 2,041 | | 2,717 |
| 1 year | 1,422.5 | | 2,717 |
| 3 years | 1,243.5 | | 2,717 |
| 5 years | 1,243.5 | | 2,717 |
| 10 years | 1,243.5 | | 2,717 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 09/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 31/10/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 31/03/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 09/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 31/05/2019 |
| Director/Board Member | 58 | 31/05/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.28% | +0.07% | +48.96% | +7.13% | 23.67B | |
| +1.08% | -3.84% | +51.50% | +160.13% | 1,031B | |
| +1.19% | -5.10% | +61.09% | +56.36% | 595B | |
| +4.21% | +0.65% | +36.48% | +87.04% | 431B | |
| +0.42% | -0.99% | +30.04% | +22.27% | 326B | |
| +1.03% | -2.10% | +28.32% | +45.08% | 277B | |
| +0.49% | -11.32% | +20.31% | +22.32% | 263B | |
| +1.59% | +3.91% | -22.47% | -36.84% | 224B | |
| +3.70% | +0.98% | +27.03% | +63.38% | 193B | |
| +3.49% | +0.35% | +24.98% | +76.58% | 164B | |
| Average | +1.75% | -3.43% | +30.62% | +50.34% | 352.8B | |
| Weighted average by Cap. | +1.65% | -4.28% | +37.87% | +78.95% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,258B 13.9B 12.15B 11.24B 10.32B 19.51B 1,339B 19.88B 133B 52.47B 655B 52.2B 51.07B | 2,074B 12.77B 11.16B 10.32B 9.48B 17.93B 1,230B 18.26B 122B 48.21B 602B 47.95B 46.91B |
| Net income | 345B 2.12B 1.85B 1.71B 1.58B 2.98B 204B 3.03B 20.29B 8.01B 99.94B 7.97B 7.79B | 328B 2.02B 1.77B 1.63B 1.5B 2.84B 195B 2.89B 19.32B 7.63B 95.19B 7.59B 7.42B |
| Net Debt | -144B -886M -774M -716M -658M -1.24B -85.34B -1.27B -8.47B -3.34B -41.74B -3.33B -3.25B | -478B -2.94B -2.57B -2.38B -2.18B -4.13B -283B -4.21B -28.13B -11.1B -139B -11.04B -10.8B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/07/26 | JP¥2,148.00 | +0.28% | 7,147,600 |
| 15/07/26 | JP¥2,142.00 | -0.19% | 6,310,600 |
| 14/07/26 | JP¥2,146.00 | +1.18% | 5,802,100 |
| 13/07/26 | JP¥2,121.00 | -0.98% | 4,304,400 |
| 10/07/26 | JP¥2,142.00 | +0.21% | 5,971,100 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
